Trustees of The University of Pennsylvania | Abramson Cancer Center

Research site

(Unclaimed)

Location

3400 Civic Center Boulevard, Philadelphia, Pennsylvania, United States of America

Site insights

Top conditions

Top treatments

Nivolumab

MK-6482

Pembrolizumab

Alectinib

MK-6482-005

Cobimetinib

VS-6063

Pertuzumab

CPI-613

Atezolizumab

Parent organization

This site is a part of Trustees of The University of Pennsylvania

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 27 total trials

Locations recently updated

A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004) (INTerpath-004)

The primary objective of the study is to compare V940 plus pembrolizumab to placebo plus pembrolizumab in participants with renal cell carcinoma (RCC...

Enrolling

Renal Cell Carcinoma

Biological: Pembrolizumab

Biological: V940

A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)

The primary objective of this study is to compare belzutifan to everolimus with respect to progression-free survival (PFS) per Response Evaluation Cr...

Active, not recruiting

Carcinoma, Renal Cell

Drug: Everolimus

Drug: Belzutifan

A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody

This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment of patients with advanced solid tumors, who relapsed whil...

Enrolling

Relapsed Cancer

Solid Tumor, Adult

Drug: HST-1011

Biological: Cemiplimab

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.

Active, not recruiting

Ovarian Neoplasms

Lung Cancer, Non-Small-Cell

Biological: CT-0508

Biological: Pembrolizumab

DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]

This study will compare DS 8201a to standard treatment.Participants must have HER2 breast cancer that has been treated before.Their cancer:* cannot b...

Active, not recruiting

Breast Cancer

Drug: Trastuzumab

Drug: Trastuzumab deruxtecan

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses (OPTIC)

The purpose of this study is to characterize the efficacy of ponatinib administered in 3 starting doses (45 mg, 30 mg, and 15 mg daily) in participan...

Active, not recruiting

Myeloid Leukemia, Chronic, Chronic Phase

Drug: Ponatinib

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in the adjuvant treatment of adult participants who have...

Active, not recruiting

Renal Cell Carcinoma

Drug: Placebo

Biological: Pembrolizumab

Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration re...

Active, not recruiting

Prostatic Neoplasms

Drug: CC1083611

Drug: CC1083610

WBSI Guided Personalized Delivery of TTFields

This research study is for Glioblastoma (GBM) patients who will be beginning Optune as part of their clinical care, which is a novel treatment that u...

Enrolling

Glioma Glioblastoma Multiforme

Tumor, Brain

Diagnostic Test: Whole Brain Spectroscopy Imaging Array Mapping Layout